Skip to main content

Dinutuximab Dosage

Medically reviewed by Drugs.com. Last updated on May 17, 2023.

Applies to the following strengths: 17.5 mg/5 mL

Usual Pediatric Dose for Neuroblastoma

17.5 mg/m2/day IV over 10 to 20 hours for 4 consecutive days for a maximum of 5 cycles:


Rate of Infusion:

Comments:
REQUIRED PRE-TREATMENT AND GUIDELINES FOR PAIN MANAGEMENT IV HYDRATION:
1) Hydration:
2) Analgesics:
3) Antihistamines and Antipyretics:

Use: In combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Permanently discontinue therapy for:


Infusion-related reactions:

Neurological Disorders of the Eye:

Capillary leak syndrome:

Hemolytic uremic syndrome:

Hyponatremia, grade 4 (despite appropriate fluid management):

Hypotension requiring medical intervention:

Severe systemic infection or sepsis:

Precautions

US BOXED WARNINGS:
Infusion Reactions:

Neurotoxicity:

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation/techniques:

Patient advice:
Patients and caregivers should be informed of these risks:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.